SCHEMBL13475429

SCHEMBL13475429

O=C(N/N=C/c1ccc2ccccc2c1)c1ccc(O)cc1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RRM1 P23921 1/20 0.79
▸ ESR1 P03372 1/20 0.70
▸ ESRRG P62508 1/20 0.70
▸ ESR2 Q92731 1/20 0.70
▸ MEN1 O00255 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ POLB P06746 2/20 0.67
▸ DNM1 Q05193 3/20 0.65
▸ ECE2 P0DPD6 2/20 0.65
▸ ECE1 P42892 2/20 0.65
▸ MUS81 Q96NY9 2/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.61
▸ GCGR P47871 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ NTRK1 P04629 2/20 0.59
▸ AR P10275 1/20 0.55
▸ FAAH O00519 1/20 0.53
▸ LMNA P02545 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830921 1.00 RRM1 (0.79) RRM1ESR1ESRRGESR2MEN1
SCHEMBL2830922 1.00 RRM1 (0.79) RRM1ESR1ESRRGESR2MEN1
SCHEMBL18963230 0.88 RRM1 (1.00) RRM1ESR1ESRRGESR2MEN1
SCHEMBL2836881 0.88 RRM1 (0.85) RRM1ESR1ESRRGESR2MEN1
SCHEMBL14983909 0.88 DNM1 (0.82) RRM1ESR1ESRRGESR2MEN1
SCHEMBL2836877 0.88 RRM1 (0.85) RRM1ESR1ESRRGESR2MEN1
SCHEMBL13475422 0.88 RRM1 (0.85) RRM1ESR1ESRRGESR2MEN1
SCHEMBL20115424 0.85 MEN1 (0.75) RRM1MEN1KMT2APOLBDNM1
SCHEMBL20299057 0.85 MEN1 (0.75) RRM1MEN1KMT2APOLBDNM1
SCHEMBL21292852 0.85 MEN1 (0.63) RRM1ESRRGMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029773-A1 Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2010-02-04 — — US disclosed
US-20100029773-A1 Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2010-02-04 — — US disclosed
EP-1751553-B1 IDENTIFICATION OF ANTI-PRION DRUGS BY HIGH-THROUGHPUT SCREENING BASED ON SIFT UNIV MUENCHEN L MAXIMILIANS (DE) 2008-10-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029773-A1 Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) PRNP, MAPT, HTT RRM1 2731/4885ESR1 4699/4885ESRRG 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback